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for SCC development in patients. Clearly, 
their findings must be confirmed in a 
larger cohort of RDEB patients afflicted 
with SCCs. However, their work high-
lights the importance of molecular epi-
demiology in patients to ascertain the 
relevancy of findings in experimental 
models of skin tumor development.
Of course, it is possible that the 
requirement of NC1 expression for SCC 
development is restricted to a subset of 
RDEB patients in which Ha-Ras muta-
tions occur. In sporadic SCCs Ras muta-
tions are infrequent and typically occur 
late in tumor progression (Campbell 
et al., 1993; Clark et al., 1993). 
Unfortunately, the activation state of Ha-
Ras in RDEB-associated SCCs is current-
ly unknown. If a high frequency of Ras 
mutations should be prevalent in RDEB-
associated SCCs, it would be of interest 
to determine whether the tumors formed 
in the absence of collagen VII expression 
exhibit deregulated signaling pathways 
normally dependent on the presence of 
either collagen VII or the NC1 domain 
(Rodeck et al., 2007). Regardless of the 
results of future efforts to resolve these 
issues, expression of the NC1 domain 
of collagen VII alone is not likely to pro-
vide a reliable diagnostic tool to iden-
tify patients at risk of SCC development. 
Instead, collagen VII joins a long list of 
extracellular matrix components that 
have been implicated in SCC develop-
ment at the microenvironment of the 
tumor–host interface, including collagen 
IV, collagen I, fibronectin, and laminin 
332 (formerly laminin 5) (Abelev and 
Lazarevich, 2006; Marinkovich, 2007). 
Much like these, collagen VII may act 
as a “modifier” of the transformed state 
by enhancing the malignant potential 
of initiated keratinocytes. Yet none of 
these extracellular matrix components is 
likely to be an absolute requirement for 
tumor progression.
RDEB, more so than less aggressive 
forms of EB, is characterized by chronic 
wound healing and excessive scar for-
mation that last decades before SCCs are 
manifest. An interesting parallel to SCCs 
arising in continuously remodeling scar 
tissue is Marjolin’s ulcers—SCCs that 
typically arise in burn scars many years 
after the initial scarring event (Phillips et 
al., 1998). Interestingly, these SCCs are 
also very aggressive and invasive, much 
like RDEB-associated SCCs. These paral-
lels raise the question of whether, regard-
less of collagen VII/NC1 expression sta-
tus, chronic wound healing represents 
the driving force for the development of 
highly malignant SCCs in both the gen-
eral population and RDEB patients.
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Genital and Nongenital Nonmelanoma 
Skin Cancer: More Epidemiological 
Studies Are Needed
Andreas Stang1
Although black men in the United States have a lower mortality of nongenital 
nonmelanoma skin cancer (NMSC) than white men, they have a higher mortal-
ity of genital NMSC than white men. Mortality of NMSC has declined over time. 
Ethnicity-specific incidence and survival analyses of NMSC can be used to deter-
mine to what degree earlier detection and/or more efficient therapies have con-
tributed to these observations.
Journal of Investigative Dermatology (2007) 127, 2296–2299. doi:10.1038/sj.jid.5700895
The burden of nonmelanoma skin cancer 
(NMSC) can be described by a variety of 
measures, including mortality. Although 
death among people with NMSC is the 
exception rather than the rule, detailed 
analyses of routinely collected mortal-
ity data provide important insights into 
the burden of disease. For example, 
although the age-standardized mortality 
rates of NMSC decreased in the territory 
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of West Germany from 1968 to 1999, 
overall 11,226 deaths due to NMSC 
occurred during this period (Stang and 
Jöckel, 2004).
Boyle et al. (2004) noted, “There is 
little information systematically col-
lected and available regarding non-
melanoma skin cancer in populations 
although there have been some very 
recent publications giving insights into 
the epidemiology of this topic.” Lewis 
and Weinstock (2007, this issue) pro-
vide new insights into the epidemiology 
of NMSC and pay special attention to 
the NMSC mortality of the genital skin. 
Although black men in the United States 
have a lower mortality rate of nongeni-
tal NMSC than white men, they have a 
higher mortality rate of genital NMSC 
than white men. This difference dimin-
ished from 1969 through 2000. Among 
white and black women, the mortality 
rates of genital NMSC were very similar 
(Lewis and Weinstock, 2007).
Generally, differences in mortality 
rates may be due to differences in dis-
ease risk (incidence) and/or of prognosis 
(survival). Although the National Cancer 
Institute’s Surveillance, Epidemiology, 
and End Results (SEER) program has data 
for only a fraction (currently 26%) of the 
US population) (Ries et al., 2006), an inci-
dence and relative survival-trend analysis 
of genital NMSC by ethnicity could give 
additional clues to the reasons for the 
differences observed between black and 
white men and women regarding genital 
NMSC. For example, incidence-trend 
analyses of vulvar cancer (ICD-9: 184. 
1-8) in East Germany during 1976–1989 
and 1998–2002 (5,121 registered cases) 
show very stable rates of about 15 per 
100,000 (World Standard Population) 
(Stang et al., 2005). If a similar stable 
incidence pattern is observed in the 
United States, the decline in mortality of 
genital NMSC among women could be 
attributed to an improvement of survival. 
Stage-specific incidence and relative 
survival analyses of genital NMSC could 
show the degree to which earlier detec-
tion (i.e., lower stage at diagnosis) and/
or more efficient therapies contributed 
to the mortality decline over time. The 
same kind of analysis by ethnicity might 
help explain the observed differences of 
NMSC mortality among black and white 
people in the United States.
Lewis and Weinstock used the results 
of their Rhode Island follow-back study 
to modify their ICD-based definition of 
NMSC-related deaths. Cancers coded 
as ICD-9 173.4 (NMSC of the scalp and 
skin of neck) were excluded from their 
definition because their follow-back 
study showed that those coded deaths 
were often caused by squamous cell 
carcinoma of mucosal surfaces (Lewis 
and Weinstock, 2004). In addition, some 
cancers that originate from the border 
between skin and mucosa—that is, vul-
var skin cancer (ICD-9: 184 exclud-
ing vagina ICD-9 184.0), perianal skin 
(ICD-9: 154.3), and malignant neo-
plasms of the vermilion border of the 
lips (ICD-9: 140.0, 140.1, 140.9)—were 
included in their definition. Non-AIDS-
related Kaposi’s sarcoma (ICD-9: 176.0) 
was also included.
If we assume that the Rhode Island 
results are generalizable to the US-wide 
mortality data, the application of their 
modified NMSC definition is appropri-
ate. However, it is unknown whether 
findings from the Rhode Island follow-
back study based on 239 deaths are 
generalizable to routine mortality sta-
tistics of other non-US health care sys-
tems. This generalization is reasonable 
only if a similar extent of miscoding 
cause of death by calendar time and 
age occurred. Unfortunately, accuracy 
studies of cause-of-death information 
on skin cancer from countries other than 
the United States are scant. In addition, 
in many countries mortality data over 
long calendar periods are not provided 
on the four-digit level of the ICD codes 
and therefore Lewis and Weinstock’s 
refined definition cannot be applied to 
these data.
For these reasons, Lewis and 
Weinstock also provided the standard 
ICD-based definition of NMSC death 
coded ICD-9 173.0–173.9. These data 
can be compared with data from other 
countries if the same age standard for the 
mortality rates is used and if one assumes 
that a similar degree of miscoding by 
calendar year and age occurred. Figure 1 
presents a comparison of NMSC mortal-
ity time trends in the United States (white 
people only) with those in West Germany 
(both US 2000 population standard) 
(Stang and Jöckel, 2004). Among men, 
Figure 1. Comparison of the age-standardized nonmelanoma skin cancer mortality rates (US 2000 
standard population) in the United States (whites) and West Germany (FRG). Mortality rates for 
white men and women in the United States derived from the SEER cancer query resource, http://seer.
cancer.gov/canques/mortality.html (accessed April 2, 2007). FRG, Federal Republic of Germany; age-
standardized mortality rates (US 2000 Standard Population) (Stang and Jöckel, 2004).
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the mortality rate of NMSC was continu-
ously higher in the United States than in 
West Germany. Interestingly, mortality 
rates due to NMSC among white women 
were higher in West Germany than in 
the United States in the early 1970s. 
West Germany showed a more or less 
monotonic decrease over time among 
both men and women. In contrast, the 
mortality due to NMSC in the United 
States showed sharp increases from 1981 
to 1988, mainly among men under 60 
years of age. This temporary increase is 
most likely due to AIDS-related Kaposi’s 
sarcomas, which at the time were coded 
under NMSC (ICD-9: 173) (Lewis and 
Weinstock, 2007). However, starting in 
the 1990s AIDS-related Kaposi’s sarco-
mas were correctly coded (up to 1998 
in the US: ICD-9, special code: 176.0; 
since 1999: ICD-10: C46.0) and more 
recent mortality rates of NMSC (since 
1999 coded according to ICD-10: C44) 
are not lower than those in the early 
1970s in the United States. In Germany, 
the HIV epidemic occurred considerably 
later and with a smaller magnitude than 
in the United States and therefore the 
temporary NMSC mortality increase due 
to AIDS-related Kaposi’s sarcoma was 
not observed.
Lewis and Weinstock’s follow-back 
study also revealed that tumors mis-
coded as NMSC occurred more fre-
quently among the younger population 
(52–74% among people aged 0–74 
years). Among the elderly (75+ years), 
miscoding occurred considerably less 
often (27–30%). A more accurate com-
parison of NMSC mortality in the United 
States and West Germany may therefore 
be possible among the elderly because 
miscoding occurs less frequently and 
AIDS-related Kaposi’s sarcoma plays 
only a marginal role. Figure 2 displays 
the age-standardized NMSC mortality 
rates of white people 65 years and older 
in the United States and West Germany. 
Among both white men and white 
women in the United States, NMSC mor-
tality rates declined from 1968 to 1979. 
Thereafter the rates remained fairly sta-
ble. AIDS-related Kaposi’s sarcoma did 
not result in a sharp increase in NMSC 
in the 1980s in the United States. The 
introduction of the ICD-10 in the United 
States in 1999 coincides with a slight 
increase in NMSC mortality, especially 
among men.
The observed West German decline 
of the NMSC age-standardized mortal-
ity rate is due mainly to a strong decline 
in NMSC among people aged 80 years 
or older (Stang and Jöckel, 2004). A 
comparison of the NMSC mortality 
rate among people 80 years or older 
between West Germany and the United 
States reveals a more similar pattern 
of decline (Figure 3). NMSC mortal-
ity rates declined up to the end of the 
1970s in both countries and among 
both white men and white women. 
Thereafter, the rates in the United States 
remained stable but further declined in 
Figure 3. Comparison of the age-standardized nonmelanoma skin cancer mortality rates (US 2000 
standard population) of people aged 80+ years in the United States (whites) and West Germany (FRG). 
Mortality rates for white men and women in the United States derived from the SEER cancer query 
resource, http://seer.cancer.gov/canques/mortality.html (accessed April 2, 2007). FRG, Federal Republic 
of Germany; age-standardized mortality rates among people aged 80+ years (US 2000 Standard 
Population) (Stang and Jöckel, 2004). 
Figure 2. Comparison of the age-standardized nonmelanoma skin cancer mortality rates (US 2000 
standard population) of people aged 65+ years in the United States (whites) and West Germany (FRG). 
Mortality rates for white men and women in the United States derived from the SEER cancer query 
resource, http://seer.cancer.gov/canques/mortality.html (accessed April 2, 2007). FRG, Federal Republic 
of Germany; age-standardized mortality rates among people aged 65+ years (US 2000 standard 
population) (Stang and Jöckel, 2004).
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West Germany. Interestingly, up to the 
mid 1990s, NMSC rates among women 
were higher in West Germany than in 
the United States.
Cancers at the border of the skin can 
pose a diagnostic problem because 
the histology of these cancers may not 
allow determination of the origin of 
the cancers, especially if carcinomas 
are undifferentiated and diagnosed at 
late stages. For example, 30.1% of all 
registered vulvar cancers other than 
melanoma in the German Democratic 
Republic from 1976 to 1989 had pen-
etrated the organ border at the time 
of diagnosis (Stang et al., 2005). The 
degree of misclassification of cancers 
at the border of the skin is thus difficult 
to quantify and may be dependent on 
a variety of factors, including diagnos-
tic opportunities such as detail of his-
topathological assessment and stage 
of diagnosis, which most likely have 
changed over recent decades. Another 
problem related to cancers of the border 
of the skin is ICD-miscoding of these 
tumors, especially if cause-of-death 
information is imprecise. For example, 
cancers of the vermillion of the lips 
(ICD-9: 140.0–140.1) can be easily 
miscoded as either skin cancer of the 
lips (ICD-9: 173.0), cancer of the inner 
aspect of the lips (ICD-9: 140.4–140.5), 
or lip cancer that overlaps two or more 
subsites within the three-digit rubric 
(ICD-9: 140.8). Lewis and Weinstock 
included 140.0–140.1 and 140.9 in 
their definition of NMSC (Lewis and 
Weinstock, 2007). Is routine cause-
of-death information accurate enough 
to allow correct distinction between 
these subcategories?
The Rhode Island follow-back study 
did not assess the accuracy of deaths 
coded as NMSC of the lips (ICD-9: 
140.0–140.1 and 140.9) or perianal 
skin (ICD-9: 154.3) and leaves unan-
swered the question of whether inclu-
sion of these deaths in the definition of 
NMSC death is appropriate (Lewis and 
Weinstock, 2004).
In conclusion, Lewis and Weinstock 
provided important new insights into the 
mortality of genital NMSC. These data are 
a good starting point for more detailed 
analyses of the (overall and stage-depen-
dent) incidence and survival of these 
tumors, which could give clues regard-
ing the observed mortality time trends of 
genital NMSC in the United States.
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Why Are Quality of Life Instruments 
Not Recognized as Reference 
Measures in Therapeutic Trials of 
Chronic Skin Disorders?
Jean Jacques Grob1
Patient-reported outcomes, especially heath-related quality of life (HRQOL) 
outcomes, are particularly relevant for chronic skin disorders (CSDs), because 
lesion scores such as PASI are less meaningful in making therapeutic deci-
sions. Patient perception of the disease impact, such as HRQOL, should 
be the main outcome measure in therapeutic trials for CSDs, especially for 
expensive biotherapies. To be credible as reference measures, dermatol-
ogy-specific instruments of HRQOL must generate similar scores in differ-
ent countries and different cultures. Because none of the currently used 
instruments—e.g., the Dermatology Life Questionnaire Index (DLQI) and 
Skindex—fulfills this requirement, it is important to generate new instruments 
or adapt existing ones.
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Instruments for recording patient-
reported outcomes, especially heath-
related quality of life (HRQOL) 
instruments, are underutilized in thera-
peutic trials for chronic skin disorders 
(CSDs), such as psoriasis, atopic der-
matitis, and chronic urticaria. They 
are, however, particularly relevant for 
these conditions. Indeed, the severity 
of these disorders is linked mainly to 
their impact on social life, patient com-
fort, and self-perception (Grob et al., 
2005). For example, although decreas-
ing the thickness, redness, or number of 
lesions according to lesion scores is cer-
tainly a valid measure of a drug’s effect 
on skin lesions, it is not a useful mea-
sure of efficacy from a patient’s point of 
view. Localized residual disease on the 
palms, face, or genital regions or a 75% 
improvement of lesion scores (PASI 
75) may still greatly affect HRQOL. A 
patient’s perception of benefits is often 
not proportional to lesion assessments 
